Barclay Friends | |
700 North Franklin, West Chester, Pennsylvania 19380 | |
(610) 696-5211 | |
Name | Barclay Friends |
---|---|
Location | 700 North Franklin, West Chester, Pennsylvania |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 96 |
Occupancy Rate | 59.17% |
Medicare ID (CCN) | 395848 |
Legal Business Name | Barclay Friends |
Ownership Type | Non Profit - Corporation |
NPI Number | 1275530735 |
Organization Name | BARCLAY FRIENDS |
Address | 700 N Franklin St, West Chester, PA 19380 |
Phone Number | 610-696-5211 |
News Archive
Doctors from the Australasian Professional Society on Alcohol and other Drugs (APSAD) strongly oppose the Federal Government's Welfare Reform Bill and its planned drug testing ‘trial' for welfare recipients.
The U.S. Food and Drug Administration today approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic), and metastatic breast cancer.
Exelixis, Inc. today reported positive preliminary data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.
Men who have a yearly blood test to examine their prostate specific antigen levels are nearly three times less likely to die from prostate cancer than those who don't have annual screenings, according to a study presented October 19, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.
Revalesio Corporation is pleased to announce a new collaboration with noted neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis.
› Verified 6 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Doctors from the Australasian Professional Society on Alcohol and other Drugs (APSAD) strongly oppose the Federal Government's Welfare Reform Bill and its planned drug testing ‘trial' for welfare recipients.
The U.S. Food and Drug Administration today approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic), and metastatic breast cancer.
Exelixis, Inc. today reported positive preliminary data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.
Men who have a yearly blood test to examine their prostate specific antigen levels are nearly three times less likely to die from prostate cancer than those who don't have annual screenings, according to a study presented October 19, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.
Revalesio Corporation is pleased to announce a new collaboration with noted neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis.
› Verified 6 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 13.61 | 14.46 |
Percentage of long-stay residents who lose too much weight | 3.76 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 85.19 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 2 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 2.17 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 0.42 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.16 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 7.63 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 92.64 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 3.42 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 27.14 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 12.44 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 4.37 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.53 | 95.98 |
Percentage of short-stay residents who made improvements in function | 63.27 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 88.31 | 82.93 |
News Archive
Doctors from the Australasian Professional Society on Alcohol and other Drugs (APSAD) strongly oppose the Federal Government's Welfare Reform Bill and its planned drug testing ‘trial' for welfare recipients.
The U.S. Food and Drug Administration today approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat cancer of the colon or rectum (colorectal cancer) that has spread to other parts of the body (metastatic), and metastatic breast cancer.
Exelixis, Inc. today reported positive preliminary data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.
Men who have a yearly blood test to examine their prostate specific antigen levels are nearly three times less likely to die from prostate cancer than those who don't have annual screenings, according to a study presented October 19, 2005, at the American Society for Therapeutic Radiology and Oncology's 47th Annual Meeting in Denver.
Revalesio Corporation is pleased to announce a new collaboration with noted neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis.
› Verified 6 days ago
Aventura At Pembrooke Location: 1130 West Chester Pike, West Chester, Pennsylvania 19380 Phone: (610) 692-3636 | |
Brandywine Hall Location: 800 West Miner Street, West Chester, Pennsylvania 19382 Phone: (610) 696-3120 | |
The Watermark At Bellingham Park Lane Location: 1615 East Boot Road East Goshen, West Chester, Pennsylvania 19380 Phone: (484) 653-4400 | |
Wellington Court Nursing And Rehab Center Location: 1361 East Boot Road, West Chester, Pennsylvania 19380 Phone: (484) 653-1200 |